Search

everythinglearnresearchcommunity

for

Search:↓

Finasteride reduced dandruff and scalp oiliness by lowering DHT, which decreases sebum production. Users also noted improvements with Nizoral and dutasteride.

The user experienced significant hair regrowth and increased density after six months of using 0.5mg Dutasteride, 5% Minoxidil foam, and Olly hair gummies daily. The user plans to discontinue the gummies, believing the medications are primarily responsible for the improvement.

The conversation is about a user's positive experience with hair regrowth using 2.5mg daily of Dutasteride and 5mg oral Minoxidil, noting significant progress without major side effects. The user experienced an initial hair shed with Dutasteride, which stopped after starting Minoxidil, and recommends consulting a doctor before adjusting dosages.

Pregnancy can temporarily reverse hair loss in women, but attempts to mimic pregnancy hormones with treatments like contraceptive pills, spironolactone, estradiol, progesterone, finasteride, and minoxidil have been ineffective. The discussion highlights the need for research into the hormonal mechanisms of pregnancy that affect hair regrowth.

A 40-year-old user shared their experience using finasteride and minoxidil for hair regrowth over a year, noting initial sexual side effects that improved after reducing the finasteride dosage. They also experienced scalp irritation from Rogaine, leading to reduced usage, and expressed satisfaction with the hair regrowth despite ongoing challenges.

The brain resists updating its perception of gradual appearance changes, like hair loss, due to its preference for stability and reliance on an internal model. This delay in perception can make changes feel sudden once the brain finally updates its model.

Finasteride and minoxidil are commonly used for hair loss, with RU58841 and microneedling also showing effectiveness. Oral minoxidil and dutasteride are noted for their impact, while side effects and alternative treatments like ketoconazole and natural DHT blockers are discussed.

A 25-year-old male experienced significant hair loss due to telogen effluvium and androgenetic alopecia. He began using finasteride, minoxidil, and vitamins, seeing some regrowth but remains worried about hair density.

A user shared progress pictures after using 1 mg finasteride and topical minoxidil for six months, hoping for further improvement by the one-year mark. The user reported no side effects and uses Head & Shoulders shampoo.

The user is experiencing asymmetrical hair loss at the frontal hairline and is concerned about potential conditions like frontal fibrosing alopecia. They have started using finasteride and pumpkin seed oil to address the issue.

A 42-year-old man used finasteride for three years, switched to dutasteride, and added oral minoxidil, resulting in stabilized hair loss and some regrowth, especially with dutasteride. He experienced no side effects and plans to consider a hair transplant in the future.

The user has been experiencing increased hair loss despite using Dutasteride, Minoxidil, and microneedling, and is considering switching back to Finasteride. They are exploring other options like hair transplants, oral Minoxidil, and red light therapy but are concerned about side effects and effectiveness.

An 18-year-old with early hair loss is advised to consider minoxidil and finasteride, with a doctor's consultation recommended. Alternatives like a hair system or shaving are suggested due to potential medication side effects and lifelong commitment.

Stevia microneedles increased minoxidil absorption and hair growth in mice. The conversation humorously questions the applicability of these results to humans.

A 24-year-old male shared his 9-month hair loss treatment journey, initially using topical finasteride and minoxidil, and recently switching to oral dutasteride and minoxidil. He experienced manageable shedding, noticeable hair density improvement, and plans to consider a hair transplant after 12-18 months on the oral treatment.

A 27-year-old is considering a hair transplant after unsuccessful minoxidil and dermarolling use, but is hesitant about finasteride due to potential side effects. Users advise trying finasteride or dutasteride to prevent further hair loss and suggest that a transplant won't stop balding without medication.

The user experienced significant hair regrowth using oral finasteride and topical minoxidil, but switching between oral and topical minoxidil led to hair loss and uncertainty about future treatment. They are considering sticking with oral minoxidil and finasteride, possibly adding dutasteride or opting for a hair transplant.

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

Minoxidil and dutasteride significantly improved hair growth, with the user experiencing initial shedding but no side effects. The user takes 2.5 mg of minoxidil and 0.5 mg of dutasteride daily, as recommended by their dermatologist.

Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.

A 34-year-old male started using 0.5mg finasteride daily and switched from topical to 2.5mg oral minoxidil two weeks ago. He noticed his hair looks thinner without noticeable shedding and is concerned about diffuse thinning.

Hair transplants in Bangkok are praised for their natural appearance, with a zigzag hairline design being favored over straight lines. The clinic Hairtran and Dr. Patty receive positive feedback, though some users express skepticism about photo filters and the authenticity of results.

The user is considering stopping topical minoxidil due to health risks and inconvenience, while continuing oral minoxidil, dutasteride, and vitamins. Others suggest that oral minoxidil carries more risk, and results from treatments may take 3-6 months to appear.

A user shared their positive experience with a 2000 graft FUE hair transplant by Dr. Ko in Korea, costing $5.4K USD, and expressed satisfaction with the results. Some users praised the outcome, while others criticized the hairline's appearance and technique.

Dutasteride, finasteride, and minoxidil are considered the top hair loss treatments. Other suggested treatments include Nizoral shampoo, tretinoin, pyrilutamide, zinc, biotin, and low light laser therapy, though opinions on their effectiveness vary.

Dutasteride 0.5 mg significantly reduces both scalp and hair follicle DHT, with a greater reduction in hair follicle DHT. The discussion questions which reduction is more important for androgenetic alopecia and diffuse thinning.

A female experienced hair loss due to low iron and an undiagnosed thyroid issue, specifically Hashimoto's, and saw improvement after starting thyroid medication, iron supplements, and making lifestyle changes. She emphasizes the importance of addressing the root cause and shares her journey to regrowth and emotional recovery.

The user uses Toppik hair fibers to thicken their hairline and has switched from finasteride to dutasteride and oral minoxidil, noticing more hair thickening. Most responses indicate the hair fibers are not noticeable, and many suggest the user doesn't need them as their hair looks natural and good for their age.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.